PEPG
PepGen LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$114.73M
P/E Ratio
—
EPS
$-2.11
Beta
2.34
52W High
$7.80
52W Low
$1.01
50-Day MA
$5.27
200-Day MA
$3.97
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and neuromuscular diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-92.22M |
| Operating Margin | 0.00% |
| Return on Equity | -67.40% |
| Return on Assets | -36.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.14 |
| Price-to-Book | 0.81 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $69.11M |
| Float | $36.97M |
| % Insiders | 0.71% |
| % Institutions | 92.62% |
Analyst Ratings
Consensus ($10.29 target)
6
Buy1
Strong SellData last updated: 4/9/2026